



October 26, 2022
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Construction of a New Plant for Drug Product Filling and Finishing

October 26 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that its Board of Directors resolved at a meeting today to construct a new plant for drug product filling and finishing (“the new plant”) on land in Kobe Science Park, which was acquired on March 24, 2022, as described below.

1. Reasons for the Construction of the New Plant

JCR, in cooperation with the adjacent new API plant (currently under construction), will construct this new fill-and-finish plant with the aid of subsidies from “Project for Establishing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production” selected by the Ministry of Economy, Trade and Industry (METI) on September 30. The objective is establishment of an integrated plant system for contract manufacturing of vaccines in case of a pandemic emergency (Click [here](#) for related news release).

JCR is a full-fledged bio-pharma with capabilities from research and development to manufacturing, and is currently developing multiple protein therapy products for the treatment lysosomal storage disorders applying its proprietary blood-brain-barrier (BBB) penetration technology, J-Brain Cargo®. The construction of this new fill-and-finish plant, will allow JCR to enhance its quality standards for global development and increase fill and finish capacities in case the facilities are not utilized for vaccine production and confectioning in case of a pandemic emergency.

2. Overview of the New Plant

(1) Property overview	[1] Begin construction: Scheduled for November, 2023 [2] Completion: Scheduled for April, 2025 [3] Scale: Formulation building three stories above ground Office building three stories above ground Warehouse building three stories above ground [4] Site area: 27,150.6m ² [5] Building area: 20,776.0m ² (planned)
(2) Location	7-3-10, Ibukidai Higashimachi, Nishi-ku, Kobe City (Click here for related news release)
(3) Total construction costs	Approx. 20 billion yen (planned)
(4) Acquisition funding	To be funded by the Project for Establishing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production subsidies and own funds
(5) Date of Board of Directors resolution	October 26, 2022

3. Future Outlook

The impact on the Company's consolidated financial results for the current fiscal year (ending March 31, 2023) is expected to be negligible.

JCR will continue to further enhance our business activities and contribute to the treatment of as many patients as possible.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

###